Key FDA Officials From Generics And Biosimilars User Fee Programs Laid Off, Said AAM
A Major Wave Of Layoffs Across Multiple FDA Departments Happened On 1 April
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
